ID: MRFR/HC/7084-HCR | February 2023 | Region: Global | 90 Pages
Market Forecast
The Pheochromocytoma Market is projected to reach USD 3169.47 Million by 2030 at 3.20% CAGR during the forecast period 2022-2030.
Market Synopsis
Pheochromocytoma is a rare type of hormone-secreting tumor that develops in the adrenal gland. Approximately 5% of all adrenal gland tumors are pheochromocytoma. The tumor is usually benign and hence does not cause cancer in most of the cases. Only 10% of the pheochromocytomas have chances to become cancerous. This adrenal gland tumor secretes the catecholamine hormones that may cause either episodic or persistent high blood pressure. The condition is similar to adrenal paraganglioma. It arises from the chromaffin cells. Approximately 25% to 35% of cases of pheochromocytoma can be due to genetic disruptions or mutations to certain genes. The rising prevalence of pheochromocytoma and increase research and development for the development of specific treatment options for the condition is expected to drive the market growth. The incidence rate of pheochromocytoma is 2 to 8 million people per year worldwide. Moreover, increasing the number of drugs in the clinical trials is also anticipated to fuel the market growth. Cabozantinib, Sunitinib, Lenvatinib, Lutathera and ONC 201 are some of the drugs which are clinical trials for use in the treatment of pheochromocytoma.
Market Influencer
An increasing number of drugs in the clinical trials are positively influencing the market growth. These drugs are cabozantinib by Exelixis, Inc., zebra by Progenics Pharmaceuticals, Inc., and Lutathera by Advanced Accelerator Applications, among others.
Market Drivers
Market Restraints
Segmentation
By Treatment Type
By End-User
By Region
Key Players
The valuation of the Pheochromocytoma Market would be USD 3169.47 Million.
The CAGR would be 3.20% during the forecast period of 2022-2030.
The surgery segment leads the market.
The hospitals and clinics segment has the charge of the market.
The Americas are leading the regional Pheochromocytoma Market.